Print

A New Risk Measurement Tool for Those at High Risk for Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/236/a-new-risk-measurement-tool-for-those-at-high-risk-for-ovarian-cancer

Clinicaltrials.gov identifier:
NCT04487405 (https://clinicaltrials.gov/show/NCT04487405)

Prevention
This study is using a new type of genetic test to measure ovarian cancer risk

Study Contact Information:

Contact: Tatiana Ferreira-Black by phone: 512-800-2885 or by email 

 


About the Study

This study is using a new type of genetic test to measure ovarian cancer risk in women who have inherited gene mutations that increase their risk for ovarian cancer or women who have an ovarian cyst or a growth in the area of the ovaries or fallopian tubes (adnexal mass). This genetic test looks at seven genetic markers and then provides a score on a scale from 0 to 20 that will tell you your risk for ovarian cancer. The higher the score, the higher your risk.

What the Study Involves

There are three groups that this study is recruiting. Each group will undergo a blood draw to use the risk measurement tool (OVAnex) so that each participant will have a risk score on a scale from 0 to 20.

  1. Group A is for women with an ovarian cyst or other benign ovarian who have symptoms from the mass
  2. Group B is for women who have an ovarian cyst or other benign mass who have no symptoms from the mass
  3. Group C is for women with an inherited gene mutation that puts them at high risk for ovarian cancer

Participants will be enrolled in the study for a total of 12 months.

Study Locations

Arizona

Georgia

Minnesota

New York

Ohio

Pennsylvania

Texas


This Study is Open To:

*Contact your doctor, the study coordinators or review the clinicaltrials.gov listing for a complete list of inclusion criteria.

This Study is Not Open To:

*Contact your doctor, the study coordinators or review the clinicaltrials.gov listing for a complete list of inclusion criteria.

 


About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.